

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number
WO 01/49712 A2

(51) International Patent Classification⁷: **C07K 14/00**

[NO/NO]; Breistølen 2, N-5035 Bergen (NO). **KROSSØY, Bjørn** [NO/NO]; Vallaheiane 133, N-5227 Nestun (NO).

(21) International Application Number: **PCT/EP01/00046**

(74) Agents: **OGILVIE EMANUELSON, C.M** et al.; P.O. Box 20, Wethouder van Eschstraat 1, NL-5340 BH Oss (NL).

(22) International Filing Date: 3 January 2001 (03.01.2001)

(81) Designated States (national): AU, CA, JP, NO, NZ, US.

(25) Filing Language: English

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(26) Publication Language: English

Published:

— *Without international search report and to be republished upon receipt of that report.*

(30) Priority Data:
00200054.5 7 January 2000 (07.01.2000) EP
00200700.3 29 February 2000 (29.02.2000) EP

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): **AKZO NOBEL N.V. [NL/NL]**; Velperweg 76, 6824 BM, NL-6824 BM Arnhem (NL).



(72) Inventors; and

(75) Inventors/Applicants (for US only): **BIERING, Eirik**

WO 01/49712 A2

(54) Title: VACCINE FOR PREVENTION AND/OR PROPHYLAXIS OF INFECTIOUS SALMON ANAEMIA IN FISH

(57) Abstract: The present invention concerns a vaccine for treatment and/or prevention of infectious salmon anaemia in fish. The invention provides for nucleic acid sequence encoding viral proteins of Infectious Salmon Anaemia Virus (ISAV) as well as the isolated (recombinant) protein, which can be used to prepare the vaccine. The invention furthermore pertains to antibodies that are reactive with said viral proteins and their use in diagnostics.

**VACCINE FOR PREVENTION AND/OR PROPHYLAXIS OF INFECTIOUS
SALMON ANAEMIA IN FISH.**

The present invention relates to isolated viral proteins of Infectious Salmon
Anaemia Virus, DNA encoding said proteins and use of said DNA or protein for
5 diagnostic or vaccine purposes.

Infectious Salmon Anaemia (ISA) is a disease in fish caused by a virus (ISAV) that belongs to the family Orthomyxoviridae. The disease is characterised by severe anaemia, leucopenia, ascites, haemorrhagic liver necrosis and petecchia of the viscera. The gills are pale, and petecchia of the skin is also common. The spleen is dark and 10 swollen (Speilberg et al, 1995; Veterinary Pathology, 32, pp. 466-478). The virus replicates in endothelial cells, both in blood vessels and in the heart, and in polymorphonuclear leukocytes. Budding of the virus from pillar cells in the gills has been observed, indicating that gills are probably an important portal of entrance for ISAV.

ISA was observed for the first time in Norway (Thorud et al., 1988; Bull. Eur. Ass. 15 Fish Pathol., 8 (5), pp. 109-111) and severe outbreaks have recently been diagnosed also in Scotland, the Shetland Islands and Canada. Mortality during outbreaks varies between 10 and 100% and younger individuals appear to be more susceptible than older. However, high mortality has also been observed among market size fish. Clinical 20 outbreaks have been observed so far in Atlantic salmon, but rainbow trout and brown trout may act as carriers of the agent without developing clinical signs. Despite stamping out strategies, new outbreaks occur regularly and result in significant losses.

Control of the disease therefore has a high priority, and the present invention provides novel means to carry out such control. The present invention provides for nucleic acid sequences encoding viral proteins of the ISAV and fragments of said 25 proteins. A first nucleic acid (SEQ ID NO 1) encodes for a protein designated Protein B of the ISAV and comprises 1083 nucleotides. This deduced amino acid sequence of Protein B is depicted in SEQ ID NO 2. A second nucleic acid sequence (SEQ ID NO 3) designated as ORF9y comprises 1737 nucleotides and encodes for another protein of ISAV. The deduced amino acid sequence of the protein encoded by ORF 9y is depicted

in SEQ ID NO 4 and comprises 578 amino acid residues. The cloning and characterisation of the nucleic acid sequence according to the invention provides for the production of proteins of the ISAV using recombinant technology (Sambrook et al., Molecular cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989). Cloning techniques and subsequent protein expression using in vitro expression systems are well known in the art. In this way, viral proteins of the ISAV can be obtained, which are substantially free from other ISAV proteins. The proteins were found to be specific for the ISA virus, which makes these proteins very suitable for use in vaccinations and diagnostics. These isolated proteins can be used in the manufacture of vaccines to protect fish against infection with ISA virus. Said vaccines may be used as marker vaccine to distinguish vaccination from field infections with ISAV. Alternatively the nucleotide sequences encoding the ISAV proteins can be used to manufacture DNA vaccines or vector vaccines to protect fish against infection with ISAV. The nucleotide sequences and recombinant proteins of the present invention can furthermore be used for diagnostic purposes, for instance to detect the presence of the ISAV or anti-ISAV antibodies in fish. Additionally, the recombinant proteins of the present invention can be used to produce ISAV specific antibodies. These antibodies can also be used for diagnostic purposes such as the detection of ISAV in fish.

Thus, in a first aspect the present invention provides for a nucleic acid sequence comprising the nucleotide sequence depicted in SEQ ID NO 1 or SEQ ID NO 3. A nucleic acid sequence comprising a fragment of the sequences depicted in SEQ ID NO 1 or 3. For the purpose of this invention a fragment is understood to consist of 10 nucleotides or more. Also within the scope of this invention are nucleotide sequences comprising tandem arrays of the sequence depicted in SEQ ID NO 1, SEQ ID NO 3, or of fragments of these sequences. Nucleotide sequences that are complementary to the sequences depicted in SEQ ID NO 1 and SEQ ID 3 or to parts of the sequences depicted in SEQ ID NO 1 or 3 are also within the scope of the invention, as well as nucleotide sequence that hybridise with the sequence depicted in SEQ ID NO 1 or SEQ ID NO 3. The hybridisation conditions for this purpose are stringent, preferably highly stringent. According to the present invention the term "stringent" means washing conditions of 1 x SSC, 0.1% SDS at a temperature of 65°C; highly stringent conditions refer to a reduction in SSC concentration towards 0.3 x SSC.

Nucleotide sequences that hybridise with the sequence shown in SEQ ID NO 1 or SEQ ID NO 3 are understood to be nucleotide sequences that have a sequence homology of at least 70%, preferably 80%, more preferably 90% with the corresponding matching part of the sequence depicted in SEQ ID NO 1 or SEQ ID NO 3. According to 5 the present invention the sequence homology is determined by comparing the nucleotide sequence with the corresponding part of the sequence depicted in SEQ ID NO 1 or 3. The sequence homology between a nucleotide sequence of interest and the sequence in SEQ ID NO 1 or 3 can be determined via common sequence analysis programs such as BLASTN and the like. The optimal match area is determined 10 automatically by these programs. Homologous sequences sequence from closely related ISAV strains can easily be isolated with the sequence depicted in SEQ ID NO 1 or SEQ ID NO 3 or with fragments of the sequences in SEQ ID NO 1 or 3 using routine cloning and hybridisation techniques (Sambrook et al., *supra*). Preferred nucleotide sequences according to the invention have a nucleotide sequence as depicted in SEQ 15 ID NO 3, SEQ ID NO 5 or SEQ ID NO 7.

The nucleotide sequences of the invention can be used in the preparation of a DNA vaccine to vaccinate fish against ISA virus infection. DNA vaccination refers to the induction of an immune response to one or more antigens that are expressed *in vivo* from a gene inserted in a DNA plasmid, which has been inoculated directly into the 20 vaccinated fish.

Thus in a second aspect of the invention there is provided for a DNA vaccine comprising a pharmaceutical acceptable carrier and a DNA plasmid in which one or more nucleotide sequences according to the invention are operably linked to a transcriptional regulatory sequence.

25 Preferably the nucleotide sequence to be used in said DNA plasmid is a nucleotide sequence comprising the nucleotide sequence depicted in SEQ ID NO 1 or fragments of the sequence of SEQ ID NO 1. Also suitable for use in said DNA plasmid are nucleotide sequences that are complementary to the sequence of SEQ ID NO 1 or nucleotide sequences that hybridise with the sequence of SEQ ID NO 1. The sequence 30 homology between the nucleotide sequences that hybridise with the sequence of SEQ ID NO 1 is determined as described earlier. More preferably a DNA vaccine according to the invention comprises a nucleotide sequence comprising the nucleotide sequence of

SEQ ID NO 1 and a nucleotide sequence comprising the sequence depicted in SEQ ID NO 3. The nucleotide sequences comprising the sequence of SEQ ID NO 3 can be on the same DNA plasmid as the nucleotide sequence comprising the sequence of SEQ ID NO 1 be or can be on a separate DNA plasmid.

5 DNA plasmids that are suitable for use in a DNA vaccine according to the invention are conventional cloning or expression plasmids for bacterial, eukaryotic- and yeast host cells, many of which are commercially available. Well-known examples of such plasmids are pBR322 and pcDNA3 (Invitrogen). The DNA plasmids according to the invention should be able to induce protein expression of the nucleotide sequences.

10 The DNA plasmid can comprise one or more nucleotide sequences according to the invention. In addition, the DNA plasmid can comprise other nucleotide sequences such as the immune-stimulating oligonucleotides having unmethylated CpG dinucleotides, or nucleotide sequences that code for other antigenic proteins or adjuvating cytokines.

Transcriptional regulatory sequences that are suitable for use in a DNA plasmid according to the invention comprise promoters such as the (human) cytomegalovirus immediate early promoter (Seed, B. et al., *Nature* 329, 840-842, 1987; Fynan, E.F. et al., *PNAS* 90, 11478-11482, 1993; Ulmer, J.B. et al., *Science* 259, 1745-1748, 1993), Rous sarcoma virus LTR (RSV, Gorman, C.M. et al., *PNAS* 79, 6777-6781, 1982; Fynan et al., *supra*; Ulmer et al., *supra*), the MPSV LTR (Stacey et al., *J. Virology* 50, 725-732, 1984), SV40 immediate early promoter (Sprague J. et al., *J. Virology* 45, 773, 1983), the metallothionein promoter (Brinster, R.L. et al., *Nature* 296, 39-42, 1982), the major late promoter of Ad2, the β -actin promoter (Tang et al., *Nature* 356, 152-154, 1992). The regulatory sequences may also include terminator and polyadenylation sequences. Amongst the sequences that can be used are the well-known bovine growth hormone polyadenylation sequence, the SV40 polyadenylation sequence, and the human cytomegalovirus (hCMV) terminator and polyadenylation sequences.

The DNA plasmid comprising a nucleotide sequence according to the present invention operably linked to a transcriptional regulatory sequence for use in the vaccine according to the invention can be naked or can be packaged in a delivery system.

30 Suitable delivery systems are lipid vesicles, Iscoms, dendromers, niosomes, polysaccharide matrices, and the like. Also very suitable as delivery system are attenuated live bacteria such as *Salmonella*.

The nucleotide sequences according to the invention can additionally be used in the production of a vector vaccine to vaccinate fish against ISA virus infection. A vector vaccine is understood to be a vaccine in which a live, attenuated bacteria or virus has been modified so that it contains one or more heterologous nucleotide sequences inserted into its genetic material. These so called vector bacteria or -viruses are capable of coexpressing the heterologous proteins encoded by the inserted nucleotides.

Thus in a third aspect the invention provides for a vector vaccine comprising a live attenuated bacteria or virus which has been modified to comprise in their genetic material one or more of the nucleotide sequences of the present invention.

Preferably the nucleotide sequence to be used in said vector vaccine is a nucleotide sequence comprising the nucleotide sequence depicted in SEQ ID NO 1 or fragments of said nucleotide sequences. More preferably the nucleotide sequence is a nucleotide sequence as depicted in SEQ ID NO 1, 5 or 7 respectively. Also suitable for use in said vector vaccine are nucleotide sequences that are complementary to the sequence of SEQ ID NO 1 or nucleotide sequences that hybridise with the sequence of SEQ ID NO 1. The sequence homology between the nucleotide sequences that hybridise with the sequence of SEQ ID NO 1 is determined as described earlier. More preferably a vector vaccine comprises live attenuated bacteria or -virus modified to express a nucleotide sequence comprising the sequence of SEQ ID NO 1 or fragments of the sequence of SEQ ID NO 1 as well as a nucleotide sequence comprising the sequence of SEQ ID NO 3 or fragments of the sequence of SEQ ID NO 3.

Very suitable for use as vaccine vectors are for example vaccinia virus or Semliki forest virus.

In a fourth aspect, the nucleotide sequences according to the invention can be used for the recombinant production of protein B and the ORF 9y protein, substantially free from other ISAV proteins. Thus, the invention provides for a protein encoded by a nucleic acid sequence comprising the sequence depicted in SEQ ID NO 1. More specifically the invention provides for a protein comprising an amino acid sequence as depicted in SEQ ID NO 2 and/or a derivative of said amino acid sequence. The invention provides furthermore for a protein encoded by a nucleic acid sequence comprising the sequence depicted in SEQ ID NO 3. More specifically the invention provides for a protein comprising an amino acid sequence as depicted in SEQ ID NO 4 and/or a

derivative of said amino acid sequence. Preferred proteins according to the invention are proteins having the amino acid sequence depicted in SEQ ID No 4, SEQ ID No 6 or SEQ ID NO 8.

Proteins comprising an amino acid sequence that is a derivative of the sequence depicted in SEQ ID NO 2 or SEQ ID NO 4 are understood to be proteins having alterations in their amino acid sequence with respect to the amino acid sequence depicted in SEQ ID NO 2 or SEQ ID NO 4, whereby said alterations do not affect the antigenic or immunogenic characteristics of the viral protein B or ORF 9y protein. For the purpose of this invention, antigenic characteristics of the Protein B and ORF 9y protein are understood to be the ability to induce production of antibodies that recognise and (cross)-react with the ISA virus. Immunogenic characteristics are understood to be the ability to induce an immune response in fish that protects against infection with ISA virus. The alterations that can occur in a sequence according to the present invention could for instance result from conservative amino acid substitutions, deletions, insertions, inversions or additions of (an) amino acid(s) in the overall sequence. Amino acid substitutions that are expected not to alter the immunological properties have been described. Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Based on this information Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 1985, vol. 227, 1435-1441) and determining the functional similarity between proteins and peptides having sequence homology. The derivative proteins according to the invention are still capable to function as the native protein or are still capable of inducing production of antibodies that recognise and (cross)-react with the ISA virus. Other derivatives according to the present invention are protein fragments that are still capable of inducing production of antibodies that recognise and (cross)-react with ISA virus or of inducing an immune response in fish that protects against infection with ISA virus. Such fragments preferably consist of 10 or more amino acid residues.

The proteins according to the invention can be prepared via standard recombinant protein expression techniques. For this purpose a nucleotide sequence

according to the invention encoding Protein B or the ORF 9y protein, a derivative protein of Protein B or the ORF 9y protein or a multimer of said proteins is inserted into an expression vector. Preferably the nucleotide sequence comprises the nucleotide sequence depicted in SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5, SEQ ID NO 7 or one or more fragments of said depicted sequences. Also suitable are nucleotide sequences that are complementary to the sequence of SEQ ID NO 1, 3, 5 or 7. Also within the scope of the invention are nucleotide sequences of which the sequence homology with the sequence depicted in SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5, or SEQ ID NO 7 is at least 70%, preferably 80%, more preferably 90%. The sequence homology between the nucleotide sequences that are suitable for use in the DNA plasmid is determined as described earlier.

Suitable expression vectors are, amongst others, plasmids, cosmids, viruses and YAC's (Yeast Artificial Chromosomes) which comprise the necessary control regions for replication and expression. The expression vector can be brought to expression in a host cell. Suitable host cells include but are not limited to bacteria, yeast cells, insect cells and mammalian cells. Such expression techniques are well known in the art (Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989). Following expression, the expressed proteins can be isolated and purified from the medium.

In a further aspect the invention provides for a vaccine comprising at least a protein according to the present invention and a pharmaceutical acceptable carrier. Preferably, the protein for use in a vaccine according to the invention comprises an amino acid sequence depicted in SEQ ID NO 2 and/or a derivative of said amino acid sequence. A preferred protein for use in a vaccine according to the invention are a protein having the amino acid sequence depicted in SEQ ID NO 6 or SEQ ID NO 8. Also preferred is a vaccine comprising a mixture of a protein comprising an amino acid sequence depicted in SEQ ID NO 2 or a derivative of the sequence depicted in SEQ ID NO 2 and a protein comprising an amino acid sequence depicted in SEQ ID NO 4 and/or a derivative of the sequence depicted in SEQ ID NO 4. Surprisingly such a vaccine induced better protection in fish against infectious salmon anaemia due to a synergistic effect between said proteins. Preferably a vaccine comprises a mixture of a

protein having the amino acid sequence depicted in SEQ ID NO 6 or SEQ ID NO 8 and a protein having the amino acid sequence depicted in SEQ ID NO 4.

Vaccines according to the invention can be prepared according to techniques well known to the skilled practitioner.

5 Vaccines according to the invention comprise an effective amount of an immunogen according to the invention and a pharmaceutical acceptable carrier. The term "effective " as used herein is defined as the amount sufficient to induce an immune response in the target fish. An immunogen according to the invention comprises a DNA plasmid in which one or more nucleotide sequences according to the invention are 10 operably linked to a transcriptional regulatory sequence, a vaccine vector comprising one or more nucleic acids according to the invention, or a protein according to the invention. The amount of plasmid, vector or protein will depend on the type of plasmid or vector, the route of administration, the time of administration, the species of the fish as well as age, general health and diet.

15 In general, a dosage of 0.01 to 1000 µg protein per kg body weight, preferably 0.5 to 500, more preferably 0.1 to 100 µg protein can be used. With respect to the DNA vaccines, generally a minimum dosage of 10 pg. up to dosages of 1000 µg have been described to be sufficient for a suitable expression of the antigens in vivo.

20 Pharmaceutical acceptable carriers suitable for use in a vaccine according to the invention are sterile water, saline, aqueous buffers such as PBS and the like. In addition a vaccine according to the invention may comprise other additives such as adjuvants, stabilisers, anti-oxidants and others.

25 Suitable adjuvants include, amongst others, aluminium hydroxide, aluminium phosphate, amphigen, tocophenols, monophosphoryl lipid A, muramyl dipeptide, oil emulsions, glucans, cytokines and saponins such as Quill A. The amount of adjuvant added depends on the nature of the adjuvant itself.

30 Suitable stabilisers for use in a vaccine according to the invention are for example carbohydrates including sorbitol, mannitol, starch, sucrose, dextrin, and glucose, proteins such as albumin or casein, and buffers like alkaline phosphates.

35 The vaccines according to the invention are administered to the fish via injection, spray, immersion or per oral. The administration protocol can be optimised in accordance with standard vaccination practice.

The nucleotide sequences and the proteins according to the invention are also suitable for use in diagnostics. The nucleotide sequences or fragments thereof can be used to detect the presence of ISAV in fish. A sample of fish infected with ISAV will comprise nucleic acid material derived from said virus, including nucleic acid sequences encoding Protein B. Suitable methods for the detection of nucleic acid sequences that are reactive with the nucleic acid sequences of the present invention include hybridisation techniques including but not limited to PCR techniques and NASBA techniques. Nucleic acid fragments of 10 or more nucleotides are particularly suitable for use as probe in hybridisation assays or primer in amplification assays such as PCR.

The proteins according to the present invention can be used to detect the presence of anti-Protein B-antibodies in the fish. Since Protein B is characteristic for the ISA virus, the presence of antibodies against the Protein B in fish is an indication of infection with ISA virus. In general, these antibodies can be detected by an immunoassay comprising the steps of:

- 15 (i) incubating a sample suspected of containing antibodies against ISAV with Protein B antigen,
- (ii) allowing the formation of antibody-antigen complex, and
- (ii) detecting the presence of the antibody-antigen complex.

The design of this immunoassay may vary. For example, the immunoassay may be based upon competition or direct reaction. Furthermore, protocols may use solid supports or may use cellular material. The detection of the antibody-antigen complex may involve the use of labelled antibodies; the labels may be, for example, enzymes, fluorescent-, chemiluminescent-, radio-active- or dye molecules.

Suitable methods for the detection of antibodies reactive with a protein according to the present invention in the sample include the enzyme-linked immunosorbent assay (ELISA), immunofluorescent test (IFT) and Western blot analysis.

The proteins according to the invention can additionally be used for the production of antibodies, using the general techniques available to the practitioner in the field. Antibodies that are produced with a protein according to the invention have the advantage of specifically reacting with Protein B of ISA virus. Preferably the proteins are used to produce specific monoclonal antibodies. The obtained antibodies may be utilised in diagnostics, to detect the presence of ISAV in the fish.

Thus, in another aspect, the present invention provides for a diagnostic kit comprising a suitable means for detection and one or more nucleotide sequences according to the invention, or one or more proteins according to the invention, or antibodies obtained with said proteins, respectively.

5 Antibodies according to the invention can be prepared according to standard techniques. Procedures for immunising animals, e.g. mice with proteins and selection of hybridomas producing immunogen specific monoclonal antibodies are well known in the art (see for example Coligan et al. (eds), Current protocols in Immunology, 1992; Kohler and Milstein, *Nature* 256:495-497, 1975; Steenbakkers et al., *Mol. Biol. Rep.* 19:125-10 134, 1994). The antibody is preferably a monoclonal antibody.

Legend to figures

Figure 1 (ISA 008): Cumulative mortality after challenge with ISAV Bremnes 98 in presmolts of Atlantic Salmon (*Salman salar*) vaccinated with 0.2 ml vaccine suspensions or saline. 1H = vaccination with 50 µg irrelevant protein, positive control. 15 9Y = vaccination with 50 µg 9Y protein. 9Z = vaccination with 5µg 9Z protein. 9Y/9Z = vaccination with a mixture of 50 µg 9Y and 5µg 9Z protein. Saline = vaccination with saline, negative control.

Figure 2 (ISA 009): Cumulative mortality after challenge with ISAV Bremnes 98 in presmolts of Atlantic Salmon (*Salman salar*) vaccinated with 0.2 ml vaccine suspensions or saline. 9Z = vaccination with 50 µg 9Z protein. 9Z-M = vaccination with 50 µg 9Z-M protein. 9Z/9Z-M = vaccination with a mixture of 50 µg 9Z and 50 µg 9Z-M protein. Saline = vaccination with saline, negative control. 20

25 MATERIALS AND METHODS

Virus isolation and construction of cDNA library

Kidney samples were taken from Atlantic salmon (*Salmo salar L.*) during an outbreak of ISA at Bremnes (Norway) in 1998. The samples were homogenized and cleared by centrifugation before filtration (0.2 µm). The homogenates were diluted 1:100

in phosphate buffered saline and incubated for 3 h at 15 °C in cell culture flasks with mono layers of ASK (Atlantic Salmon Kidney) cells. The inoculum was then replaced by cell culture medium (L-15 supplemented with 5% FCS, 50 µg ml⁻¹ gentamicin and 4 mM L-glutamine) and the cultures were incubated at 15 °C.

5 RNA was isolated from ISAV infected ASK cells using the Trizol reagent (Life Technologies). Cells were infected with ISAV and total RNA was isolated at days 2, 3 and 4 post infection. The RNA was pooled and 2 µg was used for cDNA synthesis with the cDNA Synthesis Kit (Stratagene). A unidirectional bacteriophage Lambda cDNA library was then constructed using the Uni-ZAP XR vector and Gigapack III Gold 10 packaging extract (Stratagene).

Screening of bacteriophage Lambda cDNA library

SEQ ID 1 and 5 were identified by immunoscreening with a polyclonal anti ISAV rabbit sera (see below) using the picoBlue Immunoscreening Kit (Stratagene). PCR products from clones suspected to be ISAV derived were produced using vector primers 15 and the products were sequenced. One set of internal PCR primers was constructed for each sequence, and this primer pair was employed on cDNA from ISAV infected cells and uninfected cells to determine whether the sequence was viral. The pBlueScript plasmid was then excised from ISAV positive clones using the ExAssist helper phage and the SOLR strain of *E. coli* (Stratagene). Complete sequencing was performed on 20 the isolated plasmids. SEQ ID NO 3 was identified by negative selection. [³²P]dATP labeled probes were prepared against the known viral genes using the Prime-It II Random Primer Labeling Kit (Stratagene). Plaque screening was performed according to standard procedures (1), and negative clones were selected. PCR products were sequenced, and an internal primer set was constructed for those sequences not 25 identified as known cellular genes. This primer pair was employed on cDNA from ISAV infected cells and control cells to determine whether the sequence was viral. The pBlueScript plasmid was then excised from ISAV positive clones, and complete sequencing was performed on the isolated plasmids. To obtain full-length cDNA sequences, 5' RACE was performed with the 5'RACE System, Version 2.0 (Life 30 Technologies). RACE products were cloned into the pCR 2.1-TOPO vector using the TOPO TA Cloning Kit (Invitrogen) and sequenced as described below.

DNA sequencing and assembly

Plasmids and PCR products were sequenced using the BigDye Terminator Sequencing Kit and an ABI 377 DNA analyzer (PE Biosystems). Sequences were assembled with the Sequencher software (Gene Codes Corporation). GeneBank searches were done with BLAST (2.0).

Preparation of antisera

ISAV virions were purified on a continuous sucrose gradient as previously described (4). Polyclonal antisera were prepared by immunizing rabbits three times with six weeks intervals using approximately 50 µg of purified ISAV for each immunization. The first and second immunizations was administered subcutaneously in Freund's complete and Freund's incomplete adjuvants (Difco) respectively. The third immunization was administered intravenously in saline. The animals were bled 10 days post third immunization. Peptide antisera were prepared against the predicted proteins by Eurogentec (Belgium) using the peptides DQHRTTGDEARFTC (SEQ ID NO 9)+ CEPCSVKPKTQRYGKLS (SEQ ID NO 10) for the protein depicted in SEQ ID NO 4 (designated 9Y) and MGDSRSDQSRVNPQSC (SEQ ID NO 11) + CPKMKVDFDQTSLGNT (SEQ ID NO 12) for the proteins depicted in SEQ ID No's 2, 6 and 8 (designated as 9Z-T, 9Z and 9Z-M). The peptides for each sequence were coupled to keyhole limpet haemocyanin, pooled and injected into 2 rabbits according to Eurogentec's procedures.

Northern blot analysis

Northern blotting was performed with the Northern Max Kit (Ambion). Briefly, approx. 15 µg of total RNA from ISAV infected ASK cells (3 days post infection) or from uninfected cells were separated by formaldehyde-agarose gel electrophoresis and blotted onto Hybond N nylon membranes (Amersham Pharmacia Biotech). Probes were prepared and used according to the DIG High Prime Labeling and Detection Starter Kit 2 (Boehringer Mannheim). The DIG Labeled RNA molecular weight marker 1 (Boehringer Mannheim) was run in parallel.

Baculovirus expression of 9Y and 9Z cDNA

9Y, 9Z-T and 9Z cDNA (SEQ ID NO's 3, 1 and 5, respectively) was amplified by PCR and cloned into the vector pFastBac1 (Life Technologies). 9Z-M cDNA (9Z-T cDNA with a melittin signal preceding the ORF; complete sequence depicted in SEQ ID NO 7) was also constructed. The melittin cDNA comprises nucleotide 6 to 69 of SEQ ID NO 7, and is linked by a linker sequence to the 9Z-T ORF which starts at nucleotide 84 of SEQ ID NO 7. The primers are given in Table 1.

Table 1. Primers and restriction enzymes used for cloning of different ISAV sequences into pFastBac1.

Construct	Primers	Insert cut with	Vector cut with
9Y	5'-ttggcgccacgagctgttcaagat-3' (seq id no 13)	<i>Bss HII</i> <i>Kpn I</i>	<i>Bss HII</i> <i>Kpn I</i>
	5'-gggttacccaacttattgggtactgactg-3' (seq id no 14)		
9Z	5'-ttggcgccaaagatggcacgattc-3' (seq id no 15)	<i>Bss HII</i> <i>Kpn I</i>	<i>Bss HII</i> <i>Kpn I</i>
	5'-gggttaccgttgtctttcttcataatc-3' (seq id no 16)		
9Z-T and 9Z-M	5'-aggcctaatgggtgactctcgaaagc-3' (seq id no 17)	<i>Stu I</i> <i>Kpn I</i>	<i>Stu I</i> <i>Kpn I</i>
	5'-ctcgacaagcttggtaccgtgtct-3' (seq id no 18)		

The constructs were transformed into TOP 10 cells (Invitrogen) and the isolated plasmids were used to transform DH10Bac competent cells (Life Technologies).

15 Recombinant baculoviruses were constructed according to Life Technologies' recommendations.

Immunefluorescence on Sf9 cells

Sf9 cells infected with 9Y, 9Z, 9Z-M and 9Z-T recombinant baculovirus were grown in microtiter plates at 28°C. At 5 days post infection, the cells were fixed in 96% ethanol and air dried. Cells were incubated with the polyclonal rabbit antiserum for 1 hour at 37°C. After washing with PBS, fluorescein isothiocyanate conjugated goat α rabbit IgG (KPL) was added, and cells were incubated at 37°C for 1 hour. After washing, the cells were mounted with glycerol-saline and examined using an ultra violet microscope. Sf9 cells infected with a recombinant baculovirus without insert were used as negative control.

10 *SDS-PAGE and Western blotting*

Lysates of Sf9 cells or purified ISAV were separated on discontinuous SDS-PAGE gels (4% stacking and 12% separating gels) at 200 V for 40 min. Proteins were blotted onto nitrocellulose by electrophoresis at 100 V for 60 min. After blocking and washing, the membranes were incubated with peptide sera or polyclonal antisera followed by a peroxidase conjugated goat α rabbit IgG serum (BioRad).

Hemadsorption assay

Blood was sampled from Atlantic salmon and washed three times in L-15 medium (Bio Wittaker) by centrifugation (110 x g for 10 min at 4°C). The cells were then centrifuged for five min at 170 x g (4°C), and a 5 % solution was made in L-15 (100 μ l cells + 9.9 ml L-15). This suspension was diluted 10 times in L-15 and added to cell monolayers (5 ml to a 25 cm^2 tissue culture flask) infected with recombinant or empty baculovirus. The cells were incubated at room temperature for 45 min, washed with L-15 to remove unattached erythrocytes and finally examined in an inverted microscope.

Vaccination experiment)

25 Lysate of Sf9 cells infected with 9Y, 9Z, 9Z-T and 9Z-M recombinant baculovirus were emulgated in a non-mineral oil and volumes of 0.2 ml injected into Atlantic salmon (*Salmo salar*) presmolts. The vaccine dosages of 0.2 ml contained about 50 μ g of recombinant protein (with exception of the 9Z vaccine in experiment 008 (fig. 1) were 0.2 ml was found to contain 5.0 μ g recombinant protein). Control fish were injected with 30 saline or a vaccine based upon an irrelevant protein not inducing immune response

against ISAV. The fish were kept in individual tanks, and challenged 10 weeks post vaccination by intra peritoneal injection of ISAV Bremnes 98. Results are shown in figures 1 and 2.

Results and conclusions

5 Cloning and sequence determination of an ISAV cDNA

Immunoscreening of the bacteriophage Lambda cDNA library with the polyclonal serum prepared against whole virus identified a possible ISAV clone with an open reading frame (ORF) of 1167 bases. The clone was tentatively designated 9Z. The 9Z ORF encodes a protein with predicted molecular weight of 42.4 kDa. 9Z specific PCR primers 10 amplified a product from ISAV infected ASK cells and not from uninfected cells. Also, a DIG labeled 9Z specific DNA probe prepared using the same primers hybridized with total RNA from ISAV infected ASK cells and not with RNA from uninfected cells. The ISAV conserved motif agcaaagat (3;5) was present immediately upstream of the ORF. Together, this clearly demonstrates that the 9Z sequence is ISAV derived and not of 15 cellular origin. Accordingly, primers derived from and probes complementary to the 9Z sequence are useful as diagnostic tools for ISA.

Negative selection using [³²P]dATP labeled probes against all known ISAV genes identified 1 additional viral gene. The sequence contained an ORF of 1737 bases and was designated 9Y. The 9Y ORF encodes a protein with theoretical molecular weight 20 65.2 kDa. PCR primers from the 9Y sequence amplified a product from ISAV infected ASK cells and not from uninfected cells. Also, a DIG labeled DNA probe prepared using the same primers hybridized with total RNA from ISAV infected ASK cells and not with RNA from uninfected cells. Upstream of the 9Y ORF, we found the motif agctaagat. Together, this clearly demonstrates that the 9Y sequence is ISAV derived and not of 25 cellular origin. Accordingly, primers derived from and probes complementary to the 9Y sequence are useful as diagnostic tools for ISA.

Expression of 9Y and 9Z

Expression of the 9Z cDNA in baculovirus infected Sf9 cells resulted in a protein with molecular weight approximately 43 kDa that reacted with the polyclonal antiserum 30 prepared against whole virus and with the peptide serum in Western blotting. Lysate of

Sf9 cells infected with empty baculovirus was negative. These sera also detected a similar protein in purified virus. Accordingly, a viral protein had been expressed in the Sf9 cells. The polyclonal antiserum and the peptide serum also reacted with Sf9 cells infected with 9Z-recombinant baculovirus in IFAT, but not to cells infected with empty baculovirus. In addition, the 9Z construct reacted with the monoclonal antibody 3H6F8 in IFAT on insect cells. This monoclonal antibody has previously been shown to react with the ISAV hemagglutinin (2). Cells infected with empty baculovirus did not react with 3H6F8. A distinct hemadsorption was observed to Sf9 cells infected with 9Z-recombinant baculovirus and this hemadsorption was inhibited by addition of the polyclonal antiserum prepared against purified virus. The erythrocytes did not adsorb to cells infected with empty baculovirus. The monoclonal antibody 3H6F8 has been shown to be HA specific based on its ability to inhibit hemagglutination, neutralize virus infection in cell culture and binding to the surface of ISAV particles in immune electron microscopy reactions (2). Accordingly, it is likely that the 9Z sequence encodes the ISAV hemagglutinin, in which SEQ ID NO 1 encodes the mature protein.

Expression of the 9Z-M and 9Z-T cDNA in baculovirus infected Sf9 cells resulted in a protein with molecular weight approximately 39 kDa that reacted with the polyclonal antiserum prepared against whole virus and with the peptide serum in Western blotting. Lysate of Sf9 cells infected with baculovirus without insert was negative. Expression of the 9Y cDNA in baculovirus infected Sf9 cells resulted in a protein with molecular weight approximately 65.2 kDa.

Vaccination of salmon with 9Z reduced mortality after infection with challenge ISAV. When the dosage of 9Z protein was increased from 5 to 50 µg the mortality dropped considerably. The relatively low efficacy of vaccination with the 9Z-M protein probably results from an insufficient protein dosage. Routine experimentation will be able to establish the dosage of 9Z-M or 9Y that is sufficient to obtain an efficacious vaccine.

Surprisingly addition of the 9Y protein to a vaccine comprising 9Z or 9Z-M had a positive effect on the immune response of the fishes and consequently increased the efficacy of the vaccines based on recombinant 9Z or 9Z-M alone.

Reference List

1. 1998. Current Protocols In Molecular Biology. John Wiley & Sons, Inc.
- 5 2. **Falk, K., E. Namork, and B. H. Dannevig.** 1998. Characterization and applications of a monoclonal antibody against infectious salmon anaemia virus. *Dis Aquat Org* **34**:77-85.
- 10 3. **Krossoy, B., I. Hordvik, F. Nilsen, A. Nylund, and C. Endresen.** 1999. The putative polymerase sequence of infectious salmon anemia virus suggests a new genus within the Orthomyxoviridae. *J Virol* **73**:2136-42.
4. **Mjaaland, S., E. Rimstad, K. Falk, and B. H. Dannevig.** 1997. Genomic characterization of the virus causing infectious salmon anemia in Atlantic salmon (*Salmo salar* L.): an orthomyxo-like virus in a teleost. *J Virol* **71**:7681-6.


Claims:

1. Vaccine for protecting fish against infectious salmon anaemia characterised in that said vaccine comprises at least a protein encoded by a nucleic acid sequence comprising the nucleotide sequence depicted in SEQ ID NO 1 and/or a protein encoded by a nucleic acid sequence comprising the nucleotide sequence depicted in SEQ ID NO 3, and a pharmaceutically acceptable carrier.
2. Vaccine according to claim 1 characterised in that the vaccine comprises a protein encoded by the nucleic acid sequence depicted in SEQ ID NO 5 or 7.
3. Vaccine according to claim 1 characterised in that the vaccine comprises a protein comprising the amino acid sequence depicted in SEQ ID No 2.
4. Vaccine according to claim 3 characterised in that the vaccine comprises a protein having the amino acid sequence depicted in SEQ ID No 6 or 8 and optionally a protein having the amino acid sequence depicted in SEQ ID No 4.
5. Nucleic acid comprising the nucleic acid sequence depicted in SEQ ID NO 1 or SEQ ID NO 3.
6. Protein encoded by a nucleic acid sequence according to claim 5.
7. Protein according to claim 6 characterised in that said protein comprises an amino acid sequence as depicted in SEQ ID NO 2, SEQ ID NO 4, SEQ ID No 6 or SEQ ID No 8.
8. Pharmaceutical composition comprising a nucleic acid according to claim 5, or a protein according to claims 6 or 7, and a pharmaceutical acceptable carrier.
9. Vaccine comprising a pharmaceutically acceptable carrier and a DNA plasmid, said DNA plasmid comprising at least a nucleotide sequence according to claim 5 operably linked to a transcriptional regulatory sequence.
10. Use of a nucleic acid sequence according to claim 5 for the manufacture of a DNA vaccine for treatment and/or prophylaxis of infectious salmon anaemia in fish.

11. Use of a protein according to claim 6 or 7 for the manufacture of antibodies that are specific for infectious salmon anaemia virus.
12. Antibodies raised against a protein according to claim 6 or 7.
13. A nucleic acid according to claim 5 or a protein according to claims 5 or 6 for use in diagnostics.
14. A diagnostic composition comprising a nucleic acid according to claims 1 or 2, or a protein according to claims 3-5, or antibodies that are reactive with the proteins according to claims 3-5.
15. A diagnostic kit comprising suitable detection means and a nucleic acid according to claims 1 or 2, or a protein according to claims 3-5, or antibodies that are reactive with a protein according to claims 3-5.


1/2

Figure 1



2/2

Figure 2



SEQUENCE LISTING

<110> Akzo Nobel NV

<120> Vaccine for prevention and/or prophylaxis of
Infectious Salmon Anaemia in Fish

<130> I/2000526

<140>

<141>

<150> EP00200054.5

<151> 2000-01-07

<150> EP00200700.3

<151> 2000-02-29

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 1083

<212> DNA

<213> infectious salmon anaemia virus

<220>

<221> CDS

<222> (1)..(1083)

<400> 1

atg ggt gac tct cga agc gat cag tcc aga gtg aat cca cag tct ttg 48
Met Gly Asp Ser Arg Ser Asp Gln Ser Arg Val Asn Pro Gln Ser Leu
1 5 10 15

gat ctg gtg act gag ttc aag ggg gtg ctg cag gcc aaa aac gga aat 96
Asp Leu Val Thr Glu Phe Lys Gly Val Leu Gln Ala Lys Asn Gly Asn
20 25 30

gga ctt ttg aag cag atg agt gga agg ttt cca agt gac tgg tac aca 144
Gly Leu Leu Lys Gln Met Ser Gly Arg Phe Pro Ser Asp Trp Tyr Thr
35 40 45

cct act aca aag tac cgg atc cta tac ttg gga acc aat gac tgc act 192
Pro Thr Thr Lys Tyr Arg Ile Leu Tyr Leu Gly Thr Asn Asp Cys Thr
50 55 60

gac gga cct act gac atg atc atc cca act tcg atg aca ctg gac aac	240
Asp Gly Pro Thr Asp Met Ile Ile Pro Thr Ser Met Thr Leu Asp Asn	
65 70 75 80	
gcg gca agg gag ctg tac ctg gga gca tgc agg gga gac gtg aga gtg	288
Ala Ala Arg Glu Leu Tyr Leu Gly Ala Cys Arg Gly Asp Val Arg Val	
85 90 95	
acg cct aca ttt gtg gga gcg gca att gtt gga ctt gtt gga cga aca	336
Thr Pro Thr Phe Val Gly Ala Ala Ile Val Gly Leu Val Gly Arg Thr	
100 105 110	
gac gca att acc ggt ttt tcg gtg aag gtg ttg act ttc agc agc cct	384
Asp Ala Ile Thr Gly Phe Ser Val Lys Val Leu Thr Phe Ser Ser Pro	
115 120 125	
aca att gta gtg gtg gga ttg aat gga atg tcc gga atc tac aag gtc	432
Thr Ile Val Val Val Gly Leu Asn Gly Met Ser Gly Ile Tyr Lys Val	
130 135 140	
tgc att gca gca aca tct ggg aat gtg gga gga gtg gca ctg atc aac	480
Cys Ile Ala Ala Thr Ser Gly Asn Val Gly Val Ala Leu Ile Asn	
145 150 155 160	
gga tgc gga tat ttc aac aca cct ttg agg ttt gac aat ttc caa gga	528
Gly Cys Gly Tyr Phe Asn Thr Pro Leu Arg Phe Asp Asn Phe Gln Gly	
165 170 175	
caa atc tac gtg tca gac acc ttt gaa gtg agg gga acc aaa aac aag	576
Gln Ile Tyr Val Ser Asp Thr Phe Glu Val Arg Gly Thr Lys Asn Lys	
180 185 190	
tgt gtt cta cta aga tct tct agt gat aag cct ttg tgt tca cac atc	624
Cys Val Leu Leu Arg Ser Ser Asp Lys Pro Leu Cys Ser His Ile	
195 200 205	
atg agg aac gtt gag cta gat gag tat gta gac aca cca aat aca ggg	672
Met Arg Asn Val Glu Leu Asp Glu Tyr Val Asp Thr Pro Asn Thr Gly	
210 215 220	
ggt gtt tat cct tct gat ggt ttt gat tca cta cat ggt tca gct tcc	720
Gly Val Tyr Pro Ser Asp Gly Phe Asp Ser Leu His Gly Ser Ala Ser	
225 230 235 240	
gtt aga acg ttc ctc act gat gca ttg aca tgc cca gac att gac tgg	768
Val Arg Thr Phe Leu Thr Asp Ala Leu Thr Cys Pro Asp Ile Asp Trp	
245 250 255	

agt aga att gat gct gct tcg tgt gaa tat gac agc tgc cct aag atg 816
 Ser Arg Ile Asp Ala Ala Ser Cys Glu Tyr Asp Ser Cys Pro Lys Met
 260 265 270

gtt aaa gat ttt gac cag aca agc tta ggt aac aca gac aca ctt atc 864
 Val Lys Asp Phe Asp Gln Thr Ser Leu Gly Asn Thr Asp Thr Leu Ile
 275 280 285

atg agg gag gta gca ttg cac aag gag atg atc agt aaa ctt cag agg 912
 Met Arg Glu Val Ala Leu His Lys Glu Met Ile Ser Lys Leu Gln Arg
 290 295 300

aac atc aca gat gta gaa aca tct gtg ttg agc aac atc ttc att tct 960
 Asn Ile Thr Asp Val Glu Thr Ser Val Leu Ser Asn Ile Phe Ile Ser
 305 310 315 320

atg ggt gta gca ggt ttt ggg att gct ctg ttc cta gca ggt tgg aag 1008
 Met Gly Val Ala Gly Phe Gly Ile Ala Leu Phe Leu Ala Gly Trp Lys
 325 330 335

gca tgt att tgg att gca gca ttc atg tac aag tct aga ggt aga att 1056
 Ala Cys Ile Trp Ile Ala Ala Phe Met Tyr Lys Ser Arg Gly Arg Ile
 340 345 350

cca cca tcg aac ctg tct gtt gct tga 1083
 Pro Pro Ser Asn Leu Ser Val Ala
 355 360

<210> 2

<211> 360

<212> PRT

<213> infectious salmon anaemia virus

<400> 2

Met Gly Asp Ser Arg Ser Asp Gln Ser Arg Val Asn Pro Gln Ser Leu
 1 5 10 15

Asp Leu Val Thr Glu Phe Lys Gly Val Leu Gln Ala Lys Asn Gly Asn
 20 25 30

Gly Leu Leu Lys Gln Met Ser Gly Arg Phe Pro Ser Asp Trp Tyr Thr
 35 40 45

Pro Thr Thr Lys Tyr Arg Ile Leu Tyr Leu Gly Thr Asn Asp Cys Thr
 50 55 60

Asp Gly Pro Thr Asp Met Ile Ile Pro Thr Ser Met Thr Leu Asp Asn

65	70	75	80
Ala Ala Arg Glu Leu Tyr Leu Gly Ala Cys Arg Gly Asp Val Arg Val			
85	90	95	
Thr Pro Thr Phe Val Gly Ala Ala Ile Val Gly Leu Val Gly Arg Thr			
100	105	110	
Asp Ala Ile Thr Gly Phe Ser Val Lys Val Leu Thr Phe Ser Ser Pro			
115	120	125	
Thr Ile Val Val Val Gly Leu Asn Gly Met Ser Gly Ile Tyr Lys Val			
130	135	140	
Cys Ile Ala Ala Thr Ser Gly Asn Val Gly Val Ala Leu Ile Asn			
145	150	155	160
Gly Cys Gly Tyr Phe Asn Thr Pro Leu Arg Phe Asp Asn Phe Gln Gly			
165	170	175	
Gln Ile Tyr Val Ser Asp Thr Phe Glu Val Arg Gly Thr Lys Asn Lys			
180	185	190	
Cys Val Leu Leu Arg Ser Ser Asp Lys Pro Leu Cys Ser His Ile			
195	200	205	
Met Arg Asn Val Glu Leu Asp Glu Tyr Val Asp Thr Pro Asn Thr Gly			
210	215	220	
Gly Val Tyr Pro Ser Asp Gly Phe Asp Ser Leu His Gly Ser Ala Ser			
225	230	235	240
Val Arg Thr Phe Leu Thr Asp Ala Leu Thr Cys Pro Asp Ile Asp Trp			
245	250	255	
Ser Arg Ile Asp Ala Ala Ser Cys Glu Tyr Asp Ser Cys Pro Lys Met			
260	265	270	
Val Lys Asp Phe Asp Gln Thr Ser Leu Gly Asn Thr Asp Thr Leu Ile			
275	280	285	
Met Arg Glu Val Ala Leu His Lys Glu Met Ile Ser Lys Leu Gln Arg			
290	295	300	
Asn Ile Thr Asp Val Glu Thr Ser Val Leu Ser Asn Ile Phe Ile Ser			
305	310	315	320
Met Gly Val Ala Gly Phe Gly Ile Ala Leu Phe Leu Ala Gly Trp Lys			

325

330

335

Ala Cys Ile Trp Ile Ala Ala Phe Met Tyr Lys Ser Arg Gly Arg Ile
 340 345 350

Pro Pro Ser Asn Leu Ser Val Ala
 355 360

<210> 3

<211> 1737

<212> DNA

<213> infectious salmon anaemia virus

<220>

<221> CDS

<222> (1)..(1737)

<400> 3

atg gat aac ctc cgt gaa tgc ata aac cgc aaa aga aga cta ctt gca 48
 Met Asp Asn Leu Arg Glu Cys Ile Asn Arg Lys Arg Arg Leu Leu Ala
 1 5 10 15

cta cca gat gta cct gaa act tca gac gct ttc cta agt gat ttg aga 96
 Leu Pro Asp Val Pro Glu Thr Ser Asp Ala Phe Leu Ser Asp Leu Arg
 20 25 30

cat cta tac atg tgc gtt gct ttt tgt gac caa cac aga acc act gga 144
 His Leu Tyr Met Cys Val Ala Phe Cys Asp Gln His Arg Thr Thr Gly
 35 40 45

gac gaa gca aga ttc aca aac ctg gaa ctg ctc gat cag gac gaa gcg 192
 Asp Glu Ala Arg Phe Thr Asn Leu Glu Leu Asp Gln Asp Glu Ala
 50 55 60

ctg ggt gca cag aga gct ttc gag gcc aaa cat gga atc aaa gga ggg 240
 Leu Gly Ala Gln Arg Ala Phe Glu Ala Lys His Gly Ile Lys Gly Gly
 65 70 75 80

tca cta gga gac gta tta gac cat gag ctc aaa aaa gta att gaa ttt 288
 Ser Leu Gly Asp Val Leu Asp His Glu Leu Lys Lys Val Ile Glu Phe
 85 90 95

act ttt act tca gga agt ctg tac att gca gag caa aga aaa agg aaa 336
 Thr Phe Thr Ser Gly Ser Leu Tyr Ile Ala Glu Gln Arg Lys Arg Lys
 100 105 110

actcaa gca gac tcc atc att gtgtgtgtgtca gaa gga cta aat gac 384
 Thr Gln Ala Asp Ser Ile Ile Val Cys Val Ser Glu Gly Leu Asn Asp
 115 120 125

ttc agc gtgtca cat ggt gtgttt gac atgggtctagaaaca gga 432
 Phe Ser Val Ser His Gly Val Leu Asp Met Gly Leu Val Glu Thr Gly
 130 135 140

gtt aat gca gta aga gac ttt tgc act caa aat gga ata cca atg aag 480
 Val Asn Ala Val Arg Asp Phe Cys Thr Gln Asn Gly Ile Pro Met Lys
 145 150 155 160

atc aat cag gta gga tcc aca aga aca ccc aca ccg atc agc aca tgc 528
 Ile Asn Gln Val Gly Ser Thr Arg Thr Pro Thr Pro Ile Ser Thr Cys
 165 170 175

agc att tcc gaa caa ata aca aga cag ata aac agc act att act gac 576
 Ser Ile Ser Glu Gln Ile Thr Arg Gln Ile Asn Ser Thr Ile Thr Asp
 180 185 190

aga aaa atg gaa aat gtc ctg gca gca att gca atc aaa ccg gaa ctc 624
 Arg Lys Met Glu Asn Val Leu Ala Ala Ile Ala Ile Lys Pro Glu Leu
 195 200 205

aaa tta aca caa aaa ggg tgc aga ccc tgc aaa gaa tta gaa gac gaa 672
 Lys Leu Thr Gln Lys Gly Cys Arg Pro Cys Lys Glu Leu Glu Asp Glu
 210 215 220

aac gtgtta tgg atg gac ccg cag ttc tgt gaa att gat gaa agt ttt 720
 Asn Val Leu Trp Met Asp Pro Gln Phe Cys Glu Ile Asp Glu Ser Phe
 225 230 235 240

cct tac aga gga ggg cca tac ggg aac ttc ctg caa gaa ttg ctg ctc 768
 Pro Tyr Arg Gly Pro Tyr Gly Asn Phe Leu Gln Glu Leu Leu
 245 250 255

aca acc aac gac gta gag acc aac ggg aaa gac aga gaa gag gta gtc 816
 Thr Thr Asn Asp Val Glu Thr Asn Gly Lys Asp Arg Glu Glu Val Val
 260 265 270

aag aag ata ctg gat aac aag gca ttc act gtt gaa agc ggc gaa tgc 864
 Lys Lys Ile Leu Asp Asn Lys Ala Phe Thr Val Glu Ser Gly Glu Cys
 275 280 285

atc atc aca ata cct gac aaa atg acc tgt ttt ggc gaa cag gag aag 912
 Ile Ile Thr Ile Pro Asp Lys Met Thr Cys Phe Gly Glu Gln Glu Lys
 290 295 300

aaa aaa cca gca aca tta gat gag ata aga gtg gca gga gag agg ttc	960
Lys Lys Pro Ala Thr Leu Asp Glu Ile Arg Val Ala Gly Glu Arg Phe	
305 310 315 320	
gaa ccc agt gtg aaa cct aaa aca caa aga tac gga aag cta tca gag	1008
Glu Pro Ser Val Lys Pro Lys Thr Gln Arg Tyr Gly Lys Leu Ser Glu	
325 330 335	
aag tgg cta gaa ctt gaa aaa ttc att ttt act gct agc aag aca gaa	1056
Lys Trp Leu Glu Leu Glu Lys Phe Ile Phe Thr Ala Ser Lys Thr Glu	
340 345 350	
gtt gac act ttt ctt tca gtg gga act gag agg ctt gag tca att gga	1104
Val Asp Thr Phe Leu Ser Val Gly Thr Glu Arg Leu Glu Ser Ile Gly	
355 360 365	
gtg tgc gtg ggt gct tta cac agg gca aca aca acg agg ata atc aga	1152
Val Cys Val Gly Ala Leu His Arg Ala Thr Thr Arg Ile Ile Arg	
370 375 380	
cca atg ata caa gga gga aaa tgc tgg gga atg atg ttc aag act aag	1200
Pro Met Ile Gln Gly Gly Lys Cys Trp Gly Met Met Phe Lys Thr Lys	
385 390 395 400	
tca aag atg gga gac aca aga aag gaa tac tgc cat gca atc atc	1248
Ser Lys Met Gly Asp Thr Arg Lys Glu Gly Tyr Cys His Ala Ile Ile	
405 410 415	
ttt gga aaa gga gaa gat aaa tca ggc caa aac aga atg acc atg atg	1296
Phe Gly Lys Gly Glu Asp Lys Ser Gly Gln Asn Arg Met Thr Met Met	
420 425 430	
ggg aag aca gta tac tgg cat ttg aga gtt gta aag tcc aaa ggg gac	1344
Gly Lys Thr Val Tyr Trp His Leu Arg Val Val Lys Ser Lys Gly Asp	
435 440 445	
tgg atg gca cag caa ctg tgt gca aac aaa agc agg atc tgg caa cat	1392
Trp Met Ala Gln Gln Leu Cys Ala Asn Lys Ser Arg Ile Trp Gln His	
450 455 460	
gac ccg gaa ctc gta aca gat gga gtt aca gtg ctg atg aca cct ttc	1440
Asp Pro Glu Leu Val Thr Asp Gly Val Thr Val Leu Met Thr Pro Phe	
465 470 475 480	
tca cag aag ata gct aca att agc aga tgg aga gca atg agg ctt gac	1488
Ser Gln Lys Ile Ala Thr Ile Ser Arg Trp Arg Ala Met Arg Leu Asp	
485 490 495	

agc atg ttt cac gtc tca agt gca tgg cac cat tca cca gca tgt gaa 1536
 Ser Met Phe His Val Ser Ser Ala Trp His His Ser Pro Ala Cys Glu
 500 505 510

gct gct tca gca atg ctt aga aag ttt gtt gag ata gta cac gca ata 1584
 Ala Ala Ser Ala Met Leu Arg Lys Phe Val Glu Ile Val His Ala Ile
 515 520 525

aac caa aag aga gac tgg ggt gtt gtg gga agc atg gag gac atg gtc 1632
 Asn Gln Lys Arg Asp Trp Gly Val Val Gly Ser Met Glu Asp Met Val
 530 535 540

aag gaa gtt gaa gaa ata gga gag cat ctt caa acg gcc tgc gat ttt 1680
 Lys Glu Val Glu Glu Ile Gly Glu His Leu Gln Thr Ala Cys Asp Phe
 545 550 555 560

aga gta cat aac atg tgt aaa gcc ttg att cag aaa att gca gtc agt 1728
 Arg Val His Asn Met Cys Lys Ala Leu Ile Gln Lys Ile Ala Val Ser
 565 570 575

acc caa taa 1737
 Thr Gln

<210> 4
 <211> 578
 <212> PRT
 <213> infectious salmon anaemia virus

<400> 4
 Met Asp Asn Leu Arg Glu Cys Ile Asn Arg Lys Arg Arg Leu Leu Ala
 1 5 10 15

Leu Pro Asp Val Pro Glu Thr Ser Asp Ala Phe Leu Ser Asp Leu Arg
 20 25 30

His Leu Tyr Met Cys Val Ala Phe Cys Asp Gln His Arg Thr Thr Gly
 35 40 45

Asp Glu Ala Arg Phe Thr Asn Leu Glu Leu Leu Asp Gln Asp Glu Ala
 50 55 60

Leu Gly Ala Gln Arg Ala Phe Glu Ala Lys His Gly Ile Lys Gly Gly
 65 70 75 80

Ser Leu Gly Asp Val Leu Asp His Glu Leu Lys Lys Val Ile Glu Phe
 85 90 95

Thr Phe Thr Ser Gly Ser Leu Tyr Ile Ala Glu Gln Arg Lys Arg Lys
100 105 110

Thr Gln Ala Asp Ser Ile Ile Val Cys Val Ser Glu Gly Leu Asn Asp
115 120 125

Phe Ser Val Ser His Gly Val Leu Asp Met Gly Leu Val Glu Thr Gly
130 135 140

Val Asn Ala Val Arg Asp Phe Cys Thr Gln Asn Gly Ile Pro Met Lys
145 150 155 160

Ile Asn Gln Val Gly Ser Thr Arg Thr Pro Thr Pro Ile Ser Thr Cys
165 170 175

Ser Ile Ser Glu Gln Ile Thr Arg Gln Ile Asn Ser Thr Ile Thr Asp
180 185 190

Arg Lys Met Glu Asn Val Leu Ala Ala Ile Ala Ile Lys Pro Glu Leu
195 200 205

Lys Leu Thr Gln Lys Gly Cys Arg Pro Cys Lys Glu Leu Glu Asp Glu
210 215 220

Asn Val Leu Trp Met Asp Pro Gln Phe Cys Glu Ile Asp Glu Ser Phe
225 230 235 240

Pro Tyr Arg Gly Gly Pro Tyr Gly Asn Phe Leu Gln Glu Leu Leu
245 250 255

Thr Thr Asn Asp Val Glu Thr Asn Gly Lys Asp Arg Glu Glu Val Val
260 265 270

Lys Lys Ile Leu Asp Asn Lys Ala Phe Thr Val Glu Ser Gly Glu Cys
275 280 285

Ile Ile Thr Ile Pro Asp Lys Met Thr Cys Phe Gly Glu Gln Glu Lys
290 295 300

Lys Lys Pro Ala Thr Leu Asp Glu Ile Arg Val Ala Gly Glu Arg Phe
305 310 315 320

Glu Pro Ser Val Lys Pro Lys Thr Gln Arg Tyr Gly Lys Leu Ser Glu
325 330 335

Lys Trp Leu Glu Leu Glu Lys Phe Ile Phe Thr Ala Ser Lys Thr Glu
340 345 350

Val Asp Thr Phe Leu Ser Val Gly Thr Glu Arg Leu Glu Ser Ile Gly
355 360 365

Val Cys Val Gly Ala Leu His Arg Ala Thr Thr Thr Arg Ile Ile Arg
370 375 380

Pro Met Ile Gln Gly Gly Lys Cys Trp Gly Met Met Phe Lys Thr Lys
385 390 395 400

Ser Lys Met Gly Asp Thr Arg Lys Glu Gly Tyr Cys His Ala Ile Ile
405 410 415

Phe Gly Lys Gly Glu Asp Lys Ser Gly Gln Asn Arg Met Thr Met Met
420 425 430

Gly Lys Thr Val Tyr Trp His Leu Arg Val Val Lys Ser Lys Gly Asp
435 440 445

Trp Met Ala Gln Gln Leu Cys Ala Asn Lys Ser Arg Ile Trp Gln His
450 455 460

Asp Pro Glu Leu Val Thr Asp Gly Val Thr Val Leu Met Thr Pro Phe
465 470 475 480

Ser Gln Lys Ile Ala Thr Ile Ser Arg Trp Arg Ala Met Arg Leu Asp
485 490 495

Ser Met Phe His Val Ser Ser Ala Trp His His Ser Pro Ala Cys Glu
500 505 510

Ala Ala Ser Ala Met Leu Arg Lys Phe Val Glu Ile Val His Ala Ile
515 520 525

Asn Gln Lys Arg Asp Trp Gly Val Val Gly Ser Met Glu Asp Met Val
530 535 540

Lys Glu Val Glu Glu Ile Gly Glu His Leu Gln Thr Ala Cys Asp Phe
545 550 555 560

Arg Val His Asn Met Cys Lys Ala Leu Ile Gln Lys Ile Ala Val Ser
565 570 575

Thr Gln

<210> 5

<211> 1167

<212> DNA

<213> infectious salmon anaemia virus

<220>

<221> CDS

<222> (1)..(1167)

<400> 5

atg	gca	cga	ttc	ata	att	tta	ttc	cta	ctg	ttg	gcg	cct	gtt	tac	agt	48
Met	Ala	Arg	Phe	Ile	Ile	Leu	Phe	Leu	Leu	Leu	Ala	Pro	Val	Tyr	Ser	
1															15	

cgt	cta	tgt	ctt	aga	aac	tac	cct	gac	acc	acc	tgg	atg	ggt	gac	tct	96
Arg	Leu	Cys	Leu	Arg	Asn	Tyr	Pro	Asp	Thr	Thr	Trp	Met	Gly	Asp	Ser	
															30	

cga	agc	gat	cag	tcc	aga	gtg	aat	cca	cag	tct	ttg	gat	ctg	gtg	act	144
Arg	Ser	Asp	Gln	Ser	Arg	Val	Asn	Pro	Gln	Ser	Leu	Asp	Leu	Val	Thr	
35															45	

gag	ttc	aag	ggg	gtg	ctg	cag	gcc	aaa	aac	gga	aat	gga	ctt	ttg	aag	192
Glu	Phe	Lys	Gly	Val	Leu	Gln	Ala	Lys	Asn	Gly	Asn	Gly	Leu	Leu	Lys	
50															60	

cag	atg	agt	gga	agg	ttt	cca	agt	gac	tgg	tac	aca	cct	act	aca	aag	240
Gln	Met	Ser	Gly	Arg	Phe	Pro	Ser	Asp	Trp	Tyr	Thr	Pro	Thr	Thr	Lys	
65															80	

tac	cg	atc	cta	tac	ttg	gga	acc	aat	gac	tgc	act	gac	gga	cct	act	288
Tyr	Arg	Ile	Leu	Tyr	Leu	Gly	Thr	Asn	Asp	Cys	Thr	Asp	Gly	Pro	Thr	
															95	

gac	atg	atc	atc	cca	act	tcg	atg	aca	ctg	gac	aac	gcg	gca	agg	gag	336
Asp	Met	Ile	Ile	Pro	Thr	Ser	Met	Thr	Leu	Asp	Asn	Ala	Ala	Arg	Glu	
100															110	

ctg	tac	ctg	gga	gca	tgc	agg	gga	gac	gtg	aga	gtg	acg	cct	aca	ttt	384
Leu	Tyr	Leu	Gly	Ala	Cys	Arg	Gly	Asp	Val	Arg	Val	Thr	Pro	Thr	Phe	
115															125	

gtg	gga	gca	att	gtt	gga	ctt	gtt	gga	cga	aca	gac	gca	att	acc	432	
Val	Gly	Ala	Ala	Ile	Val	Gly	Leu	Val	Gly	Arg	Thr	Asp	Ala	Ile	Thr	
130															140	

ggt	ttt	tcg	gtg	aag	gtg	ttg	act	ttc	agc	agc	cct	aca	att	gta	gtg	480
Gly	Phe	Ser	Val	Lys	Val	Leu	Thr	Phe	Ser	Ser	Pro	Thr	Ile	Val	Val	
145															160	

gtg gga ttg aat gga atg tcc gga atc tac aag gtc tgc att gca gca	528		
Val Gly Leu Asn Gly Met Ser Gly Ile Tyr Lys Val Cys Ile Ala Ala			
165	170	175	
aca tct ggg aat gtg gga gga gtg gca ctg atc aac gga tgc gga tat	576		
Thr Ser Gly Asn Val Gly Val Ala Leu Ile Asn Gly Cys Gly Tyr			
180	185	190	
ttc aac aca cct ttg agg ttt gac aat ttc caa gga caa atc tac gtg	624		
Phe Asn Thr Pro Leu Arg Phe Asp Asn Phe Gln Gly Gln Ile Tyr Val			
195	200	205	
tca gac acc ttt gaa gtg agg gga acc aaa aac aag tgt gtt cta cta	672		
Ser Asp Thr Phe Glu Val Arg Gly Thr Lys Asn Lys Cys Val Leu Leu			
210	215	220	
aga tct tct agt gat aag cct ttg tgt tca cac atc atg agg aac gtt	720		
Arg Ser Ser Ser Asp Lys Pro Leu Cys Ser His Ile Met Arg Asn Val			
225	230	235	240
gag cta gat gag tat gta gac aca cca aat aca ggg ggt gtt tat cct	768		
Glu Leu Asp Glu Tyr Val Asp Thr Pro Asn Thr Gly Gly Val Tyr Pro			
245	250	255	
tct gat ggt ttt gat tca cta cat ggt tca gct tcc gtt aga acg ttc	816		
Ser Asp Gly Phe Asp Ser Leu His Gly Ser Ala Ser Val Arg Thr Phe			
260	265	270	
ctc act gat gca ttg aca tgc cca gac att gac tgg agt aga att gat	864		
Leu Thr Asp Ala Leu Thr Cys Pro Asp Ile Asp Trp Ser Arg Ile Asp			
275	280	285	
gct gct tcg tgt gaa tat gac agc tgc cct aag atg gtt aaa gat ttt	912		
Ala Ala Ser Cys Glu Tyr Asp Ser Cys Pro Lys Met Val Lys Asp Phe			
290	295	300	
gac cag aca agc tta ggt aac aca gac aca ctt atc atg agg gag gta	960		
Asp Gln Thr Ser Leu Gly Asn Thr Asp Thr Leu Ile Met Arg Glu Val			
305	310	315	320
gca ttg cac aag gag atg atc agt aaa ctt cag agg aac atc aca gat	1008		
Ala Leu His Lys Glu Met Ile Ser Lys Leu Gln Arg Asn Ile Thr Asp			
325	330	335	
gta gaa aca tct gtg ttg agc aac atc ttc att tct atg ggt gta gca	1056		
Val Glu Thr Ser Val Leu Ser Asn Ile Phe Ile Ser Met Gly Val Ala			
340	345	350	

ggt ttt ggg att gct ctg ttc cta gca ggt tgg aag gca tgt att tgg 1104
 Gly Phe Gly Ile Ala Leu Phe Leu Ala Gly Trp Lys Ala Cys Ile Trp
 355 360 365

att gca gca ttc atg tac aag tct aga ggt aga att cca cca tcg aac 1152
 Ile Ala Ala Phe Met Tyr Lys Ser Arg Gly Arg Ile Pro Pro Ser Asn
 370 375 380

ctg tct gtt gct tga 1167
 Leu Ser Val Ala
 385

<210> 6
 <211> 388
 <212> PRT
 <213> infectious salmon anaemia virus

<400> 6
 Met Ala Arg Phe Ile Ile Leu Phe Leu Leu Leu Ala Pro Val Tyr Ser
 1 5 10 15

Arg Leu Cys Leu Arg Asn Tyr Pro Asp Thr Thr Trp Met Gly Asp Ser
 20 25 30

Arg Ser Asp Gln Ser Arg Val Asn Pro Gln Ser Leu Asp Leu Val Thr
 35 40 45

Glu Phe Lys Gly Val Leu Gln Ala Lys Asn Gly Asn Gly Leu Leu Lys
 50 55 60

Gln Met Ser Gly Arg Phe Pro Ser Asp Trp Tyr Thr Pro Thr Thr Lys
 65 70 75 80

Tyr Arg Ile Leu Tyr Leu Gly Thr Asn Asp Cys Thr Asp Gly Pro Thr
 85 90 95

Asp Met Ile Ile Pro Thr Ser Met Thr Leu Asp Asn Ala Ala Arg Glu
 100 105 110

Leu Tyr Leu Gly Ala Cys Arg Gly Asp Val Arg Val Thr Pro Thr Phe
 115 120 125

Val Gly Ala Ala Ile Val Gly Leu Val Gly Arg Thr Asp Ala Ile Thr
 130 135 140

Gly Phe Ser Val Lys Val Leu Thr Phe Ser Ser Pro Thr Ile Val Val
 145 150 155 160

Val Gly Leu Asn Gly Met Ser Gly Ile Tyr Lys Val Cys Ile Ala Ala
165 170 175

Thr Ser Gly Asn Val Gly Gly Val Ala Leu Ile Asn Gly Cys Gly Tyr
180 185 190

Phe Asn Thr Pro Leu Arg Phe Asp Asn Phe Gln Gly Gln Ile Tyr Val
195 200 205

Ser Asp Thr Phe Glu Val Arg Gly Thr Lys Asn Lys Cys Val Leu Leu
210 215 220

Arg Ser Ser Ser Asp Lys Pro Leu Cys Ser His Ile Met Arg Asn Val
225 230 235 240

Glu Leu Asp Glu Tyr Val Asp Thr Pro Asn Thr Gly Gly Val Tyr Pro
245 250 255

Ser Asp Gly Phe Asp Ser Leu His Gly Ser Ala Ser Val Arg Thr Phe
260 265 270

Leu Thr Asp Ala Leu Thr Cys Pro Asp Ile Asp Trp Ser Arg Ile Asp
275 280 285

Ala Ala Ser Cys Glu Tyr Asp Ser Cys Pro Lys Met Val Lys Asp Phe
290 295 300

Asp Gln Thr Ser Leu Gly Asn Thr Asp Thr Leu Ile Met Arg Glu Val
305 310 315 320

Ala Leu His Lys Glu Met Ile Ser Lys Leu Gln Arg Asn Ile Thr Asp
325 330 335

Val Glu Thr Ser Val Leu Ser Asn Ile Phe Ile Ser Met Gly Val Ala
340 345 350

Gly Phe Gly Ile Ala Leu Phe Leu Ala Gly Trp Lys Ala Cys Ile Trp
355 360 365

Ile Ala Ala Phe Met Tyr Lys Ser Arg Gly Arg Ile Pro Pro Ser Asn
370 375 380

Leu Ser Val Ala
385

<210> 7
 <211> 1166
 <212> DNA
 <213> infectious salmon anaemia virus

 <220>
 <221> CDS
 <222> (6)..(1166)

 <220>
 <221> sig_peptide
 <222> (6)..(68)
 <223> melittin signal peptide

 <400> 7
 gatcc atg aaa ttc tta gtc aac gtt gcc ctt gtt ttt atg gtc gta tac 50
 Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr
 1 5 10 15

 att tct tac atc tat gcg gaa ttc aaa ggc cta atg ggt gac tct cga 98
 Ile Ser Tyr Ile Tyr Ala Glu Phe Lys Gly Leu Met Gly Asp Ser Arg
 20 25 30

 agc gat cag tcc aga gtg aat cca cag tct ttg gat ctg gtg act gag 146
 Ser Asp Gln Ser Arg Val Asn Pro Gln Ser Leu Asp Leu Val Thr Glu
 35 40 45

 ttc aag ggg gtg ctg cag gcc aaa aac gga aat gga ctt ttg aag cag 194
 Phe Lys Gly Val Leu Gln Ala Lys Asn Gly Asn Gly Leu Leu Lys Gln
 50 55 60

 atg agt gga agg ttt cca agt gac tgg tac aca cct act aca aag tac 242
 Met Ser Gly Arg Phe Pro Ser Asp Trp Tyr Thr Pro Thr Thr Lys Tyr
 65 70 75

 cgg atc cta tac ttg gga acc aat gac tgc act gac gga cct act gac 290
 Arg Ile Leu Tyr Leu Gly Thr Asn Asp Cys Thr Asp Gly Pro Thr Asp
 80 85 90 95

 atg atc atc cca act tcg atg aca ctg gac aac gcg gca agg gag ctg 338
 Met Ile Ile Pro Thr Ser Met Thr Leu Asp Asn Ala Ala Arg Glu Leu
 100 105 110

 tac ctg gga gca tgc agg gga gac gtg aga gtg acg cct aca ttt gtg 386
 Tyr Leu Gly Ala Cys Arg Gly Asp Val Arg Val Thr Pro Thr Phe Val
 115 120 125

 gga gcg gca att gtt gga ctt gtt gga cga aca gac gca att acc ggt 434

Gly Ala Ala Ile Val Gly Leu Val Gly Arg Thr Asp Ala Ile Thr Gly			
130	135	140	
ttt tcg gtg aag gtg ttg act ttc agc agc cct aca att gta gtg gtg	482		
Phe Ser Val Lys Val Leu Thr Phe Ser Ser Pro Thr Ile Val Val Val			
145	150	155	
gga ttg aat gga atg tcc gga atc tac aag gtc tgc att gca gca aca	530		
Gly Leu Asn Gly Met Ser Gly Ile Tyr Lys Val Cys Ile Ala Ala Thr			
160	165	170	175
tct ggg aat gtg gga gga gtg gca ctg atc aac gga tgc gga tat ttc	578		
Ser Gly Asn Val Gly Gly Val Ala Leu Ile Asn Gly Cys Gly Tyr Phe			
180	185	190	
aac aca cct ttg agg ttt gac aat ttc caa gga caa atc tac gtg tca	626		
Asn Thr Pro Leu Arg Phe Asp Asn Phe Gln Gly Gln Ile Tyr Val Ser			
195	200	205	
gac acc ttt gaa gtg agg gga acc aaa aac aag tgt gtt cta cta aga	674		
Asp Thr Phe Glu Val Arg Gly Thr Lys Asn Lys Cys Val Leu Ieu Arg			
210	215	220	
tct tct agt gat aag cct ttg tgt tca cac atc atg agg aac gtt gag	722		
Ser Ser Ser Asp Lys Pro Leu Cys Ser His Ile Met Arg Asn Val Glu			
225	230	235	
cta gat gag tat gta gac aca cca aat aca ggg ggt gtt tat cct tct	770		
Leu Asp Glu Tyr Val Asp Thr Pro Asn Thr Gly Gly Val Tyr Pro Ser			
240	245	250	255
gat ggt ttt gat tca cta cat ggt tca gct tcc gtt aga acg ttc ctc	818		
Asp Gly Phe Asp Ser Leu His Gly Ser Ala Ser Val Arg Thr Phe Leu			
260	265	270	
act gat gca ttg aca tgc cca gac att gac tgg agt aga att gat gct	866		
Thr Asp Ala Leu Thr Cys Pro Asp Ile Asp Trp Ser Arg Ile Asp Ala			
275	280	285	
gct tcg tgt gaa tat gac agc tgc cct aag atg gtt aaa gat ttt gac	914		
Ala Ser Cys Glu Tyr Asp Ser Cys Pro Lys Met Val Lys Asp Phe Asp			
290	295	300	
cag aca agc tta ggt aac aca gac aca ctt atc atg agg gag gta gca	962		
Gln Thr Ser Leu Gly Asn Thr Asp Thr Leu Ile Met Arg Glu Val Ala			
305	310	315	
ttg cac aag gag atg atc agt aaa ctt cag agg aac atc aca gat gta	1010		

Leu His Lys Glu Met Ile Ser Lys Leu Gln Arg Asn Ile Thr Asp Val
 320 325 330 335

gaa aca tct gtg ttg agc aac atc ttc att tct atg ggt gta gca ggt 1058
 Glu Thr Ser Val Leu Ser Asn Ile Phe Ile Ser Met Gly Val Ala Gly
 340 345 350

ttt ggg att gct ctg ttc cta gca ggt tgg aag gca tgt att tgg att 1106
 Phe Gly Ile Ala Leu Phe Leu Ala Gly Trp Lys Ala Cys Ile Trp Ile
 355 360 365

gca gca ttc atg tac aag tct aga ggt aga att cca cca tcg aac ctg 1154
 Ala Ala Phe Met Tyr Lys Ser Arg Gly Arg Ile Pro Pro Ser Asn Leu
 370 375 380

tct gtt gct tga 1166
 Ser Val Ala
 385

<210> 8

<211> 386

<212> PRT

<213> infectious salmon anaemia virus

<400> 8

Met Lys Phe Leu Val Asn Val Ala Leu Val Phe Met Val Val Tyr Ile
 1 5 10 15

Ser Tyr Ile Tyr Ala Glu Phe Lys Gly Leu Met Gly Asp Ser Arg Ser
 20 25 30

Asp Gln Ser Arg Val Asn Pro Gln Ser Leu Asp Leu Val Thr Glu Phe
 35 40 45

Lys Gly Val Leu Gln Ala Lys Asn Gly Asn Gly Leu Leu Lys Gln Met
 50 55 60

Ser Gly Arg Phe Pro Ser Asp Trp Tyr Thr Pro Thr Thr Lys Tyr Arg
 65 70 75 80

Ile Leu Tyr Leu Gly Thr Asn Asp Cys Thr Asp Gly Pro Thr Asp Met
 85 90 95

Ile Ile Pro Thr Ser Met Thr Leu Asp Asn Ala Ala Arg Glu Leu Tyr
 100 105 110

Leu Gly Ala Cys Arg Gly Asp Val Arg Val Thr Pro Thr Phe Val Gly

115	120	125
Ala Ala Ile Val Gly Leu Val Gly Arg Thr Asp Ala Ile Thr Gly Phe		
130	135	140
Ser Val Lys Val Leu Thr Phe Ser Ser Pro Thr Ile Val Val Val Gly		
145	150	155
Leu Asn Gly Met Ser Gly Ile Tyr Lys Val Cys Ile Ala Ala Thr Ser		
165	170	175
Gly Asn Val Gly Gly Val Ala Leu Ile Asn Gly Cys Gly Tyr Phe Asn		
180	185	190
Thr Pro Leu Arg Phe Asp Asn Phe Gln Gly Gln Ile Tyr Val Ser Asp		
195	200	205
Thr Phe Glu Val Arg Gly Thr Lys Asn Lys Cys Val Leu Leu Arg Ser		
210	215	220
Ser Ser Asp Lys Pro Leu Cys Ser His Ile Met Arg Asn Val Glu Leu		
225	230	235
Asp Glu Tyr Val Asp Thr Pro Asn Thr Gly Gly Val Tyr Pro Ser Asp		
245	250	255
Gly Phe Asp Ser Leu His Gly Ser Ala Ser Val Arg Thr Phe Leu Thr		
260	265	270
Asp Ala Leu Thr Cys Pro Asp Ile Asp Trp Ser Arg Ile Asp Ala Ala		
275	280	285
Ser Cys Glu Tyr Asp Ser Cys Pro Lys Met Val Lys Asp Phe Asp Gln		
290	295	300
Thr Ser Leu Gly Asn Thr Asp Thr Leu Ile Met Arg Glu Val Ala Leu		
305	310	315
His Lys Glu Met Ile Ser Lys Leu Gln Arg Asn Ile Thr Asp Val Glu		
325	330	335
Thr Ser Val Leu Ser Asn Ile Phe Ile Ser Met Gly Val Ala Gly Phe		
340	345	350
Gly Ile Ala Leu Phe Leu Ala Gly Trp Lys Ala Cys Ile Trp Ile Ala		
355	360	365
Ala Phe Met Tyr Lys Ser Arg Gly Arg Ile Pro Pro Ser Asn Leu Ser		

370

375

380

Val Ala

385

<210> 9

<211> 14

<212> PRT

<213> infectious salmon anaemia virus

<400> 9

Asp Gln His Arg Thr Thr Gly Asp Glu Ala Arg Phe Thr Cys

1

5

10

<210> 10

<211> 16

<212> PRT

<213> infectious salmon anaemia virus

<400> 10

Cys Glu Pro Ser Val Lys Pro Lys Thr Gln Arg Tyr Gly Lys Leu Ser

1

5

10

15

<210> 11

<211> 16

<212> PRT

<213> infectious salmon anaemia virus

<400> 11

Met Gly Asp Ser Arg Ser Asp Gln Ser Arg Val Asn Pro Gln Ser Cys

1

5

10

15

<210> 12

<211> 16

<212> PRT

<213> infectious salmon anaemia virus

<400> 12

Cys Pro Lys Met Val Lys Asp Phe Asp Gln Thr Ser Leu Gly Asn Thr

1

5

10

15

<210> 13
<211> 27
<212> DNA
<213> infectious salmon anaemia virus

<400> 13
ttggcgcc acgagctgtt tcaagat

27

<210> 14
<211> 29
<212> DNA
<213> infectious salmon anaemia virus

<400> 14
gggttaccca acttattggg tactgactg

29

<210> 15
<211> 25
<212> DNA
<213> infectious salmon anaemia virus

<400> 15
ttggcgcc aagatggcac gattc

25

<210> 16
<211> 28
<212> DNA
<213> infectious salmon anaemia virus

<400> 16
gggttacccgt tgtctttctt tcataatc

28

<210> 17
<211> 25
<212> DNA
<213> infectious salmon anaemia virus

<400> 17
aggcctaattt ggtgactctc gaagc

25

<210> 18

<211> 25

<212> DNA

<213> infectious salmon anaemia virus

<400> 18

ctcgacaaggc ttggtaaccgt tgtct

25